

CLAIMS

[Claim 1]

A crystal of 2-(5-chloropyridin-3-yl)-1-(2,5-dichlorobenzyl)-4-methyl-1H-imidazole-5-carboxylic acid.

[Claim 2]

The crystal according to claim 1, wherein the crystal is form A crystal having characteristic peaks at diffraction angles of $2\theta = 13.4^\circ$, 15.2° , 20.0° , 20.8° , 24.0° , 26.6° , 30.1° , 30.7° , 31.3° , and 33.0° in its X-ray powder diffraction spectrum.

[Claim 3]

The crystal according to claim 1, wherein the crystal is form A crystal having an X-ray powder diffraction spectrum pattern shown in Figure 1.

[Claim 4]

The crystal according to claim 1, wherein the crystal is form A crystal having characteristic peaks at chemical shifts of 125.8 ppm, 134.8 ppm, 136.7 ppm and 150.1 ppm in its solid-state ^{13}C -NMR spectrum.

[Claim 5]

The crystal according to claim 1, wherein the crystal is form A crystal having a solid-state ^{13}C -NMR spectrum pattern shown in Figure 3.

[Claim 6]

The crystal according to claim 1, wherein the crystal is form A crystal having a characteristic peaks at wave numbers of 1313 cm^{-1} , 1324 cm^{-1} , and 1391 cm^{-1} in its infrared absorption spectrum according to the potassium bromide disk method.

[Claim 7]

The crystal according to claim 1, wherein the crystal is form A crystal having an infrared absorption spectrum pattern shown in Figure 5 according to the potassium bromide disk method.

[Claim 8]

The crystal according to any one of claims 2 to 7, wherein its endothermic peak in thermogravimetry/differential

thermal analysis is at 234°C.

[Claim 9]

The crystal according to claim 1, wherein the crystal is form B crystal having characteristic peaks at diffraction angles of $2\theta = 10.8^\circ, 12.0^\circ, 13.8^\circ, 16.0^\circ, 19.3^\circ, 21.0^\circ, 22.4^\circ, 23.7^\circ, 26.6^\circ$, and 31.2° in its X-ray powder diffraction spectrum.

[Claim 10]

The crystal according to claim 1, wherein the crystal is form B crystal having an X-ray powder diffraction spectrum shown in Figure 2.

[Claim 11]

The crystal according to claim 1, wherein the crystal is form B crystal having characteristic peaks at chemical shifts of 16.4 ppm (double peak), 120.5 ppm, and 135.6 ppm in its solid-state ^{13}C -NMR spectrum.

[Claim 12]

The crystal according to claim 1, wherein the crystal is form B crystal having an solid-state ^{13}C -NMR spectrum pattern shown in Figure 4.

[Claim 13]

The crystal according to claim 1, wherein the crystal is form B crystal having characteristic peaks at wave numbers of 1329 cm^{-1} , 1382 cm^{-1} , and 1401 cm^{-1} in its infrared absorption spectrum according to the potassium bromide disk method.

[Claim 14]

The crystal according to claim 1, wherein the crystal is form B crystal having an infrared absorption spectrum pattern shown in Figure 6 according to the potassium bromide disk method.

[Claim 15]

The crystal according to any one of claims 9 to 14, wherein its endothermic peak in thermogravimetry/differential thermal analysis is at 236°C.

[Claim 16]

A method for producing a crystal of 2-(5-chloropyridin-3-

yl)-1-(2,5-dichlorobenzyl)-4-methyl-1H-imidazole-5-carboxylic acid, comprising the steps of:

suspending an alkyl ester of 2-(5-chloropyridin-3-yl)-1-(2,5-dichlorobenzyl)-4-methyl-1H-imidazole-5-carboxylic acid in a solvent and performing hydrolysis by adding an aqueous solution of a base thereto; and

neutralizing the reaction product.

[Claim 17]

The method for producing a crystal according to claim 16, further comprising the step of stirring the neutralized product while cooling.

[Claim 18]

The method for producing a crystal according to claim 16 or 17, wherein the solvent is a single organic solvent selected from methanol, ethanol, 2-propanol, 1-butanol, and tetrahydrofuran, or a mixture solvent of the organic solvent and water, or a mixture of two or more organic solvents selected from methanol, ethanol, 2-propanol, and 1-butanol, or a mixture solvent of the mixture of the organic solvents and water.

[Claim 19]

The method for producing a crystal according to claim 18, wherein the solvent is a single organic solvent selected from methanol, ethanol, 2-propanol, and 1-butanol, or a mixture solvent of the single organic solvent and water.

[Claim 20]

The method for producing a crystal according to claim 18, wherein the solvent is ethanol.

[Claim 21]

The method for producing a crystal according to claim 16 or 17, wherein the solvent is a mixture solvent of tetrahydrofuran and ethanol.

[Claim 22]

A pharmaceutical composition comprising the crystal according to any one of claims 1 to 15 and a pharmaceutically acceptable carrier.

[Claim 23]

A URAT1 inhibitor comprising the crystal according to any

one of claims 1 to 15 as an active ingredient.

[Claim 24]

A therapeutic or prophylactic agent for one or more diseases selected from the group consisting of gout, hyperuricemia, hypertension, renal disease, diabetes, arteriosclerosis, and Lesch-Nyhan syndrome, comprising the crystal according to any one of claims 1 to 15 as an active ingredient.